Alembic Pharmaceuticals’ associate company - Rhizen Pharmaceuticals S.A. (Rhizen) has been granted orphan-drug designation by the US Food and Drug Administration (USFDA) for the active moiety of Tenalisib, the company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of peripheral T-cell lymphoma (PTCL).
Tenalisib is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
